BRAF and MEK Targeted Therapies in Pediatric Central Nervous System Tumors

Dario Talloa, Silvia Triarico, Pierpaolo Agresti, Stefano Mastrangelo, Giorgio Attinà, Alberto Romano, Palma Maurizi, Antonio Ruggiero

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

Abstract

BRAF is a component of the MAPK and PI3K/AKT/mTOR pathways that play a crucial role in cellular proliferation, differentiation, migration, and angiogenesis. Pediatric central nervous system tumors very often show mutations of the MAPK pathway, as demonstrated by next-generation sequencing (NGS), which now has an increasing role in cancer diagnostics. The MAPK mutated pathway in pediatric CNS tumors is the target of numerous drugs, approved or under investigation in ongoing clinical trials. In this review, we describe the main aspects of MAPK and PI3K/AKT/mTOR signaling pathways, with a focus on the alterations commonly involved in tumorigenesis. Furthermore, we reported the main available data about current BRAF and MEK targeted therapies used in pediatric low-grade gliomas (pLLGs), pediatric high-grade gliomas (pHGGs), and other CNS tumors that often present BRAF or MEK mutations. Further molecular stratification and clinical trial design are required for the treatment of pediatric CNS tumors with BRAF and MEK inhibitors.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaCancers
Volume14
DOI
Stato di pubblicazionePubblicato - 2022

Keywords

  • BRAF
  • MEK
  • NGS
  • central nervous system (CNS) tumors
  • children
  • targeted therapies

Fingerprint

Entra nei temi di ricerca di 'BRAF and MEK Targeted Therapies in Pediatric Central Nervous System Tumors'. Insieme formano una fingerprint unica.

Cita questo